The first peptide drugs were replacements for endogenous signalling molecules.
Insulin and GLP1 analogues with improved in vivo half-live.
Use of display technologies to identify targeting peptides and the potential for peptide-drug conjugates.
Peptides as cost-effective alternatives to monoclonal antibodies for a range of autoimmune and inflammatory conditions.
Use of display technologies to identify novel peptides for “difficult-to-drug” targets.
Display technologies identify novel targeting and anti-microbial peptides.
This paper describes the use of the Orbit method to identify peptides which bind to the HIV GP120 and which were then shown to inhibit HIV infection via CD4 binding in a cell-based assay. A 9aa peptide was identified with similar potency to an approved product.
This paper describes probing of cell surface targets using the Orbit method. Different T-cell populations were screened for binding to T-cell receptors and peptides with appropriate structures for each T-cell population were identified.
300 delegates representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions. Over 55 presentations, case studies and panel discussions focused on the key issues in drug discovery and medicinal chemistry.